Peer Exchange

Expert endocrinologists explore the pathophysiology of type 1 diabetes (T1D) and delve into screening and staging processes. They discuss strategies for delaying its onset and provide insight into the future of T1D management.

In an upcoming Peer Exchange experts in cardiology will discuss novel treatment approaches for obstructive hypertrophic cardiomyopathy.

Experts present the current landscape of treatment for patients with fibromyalgia (FM), highlighting its pathophysiology and risk factors, the importance of integrative care, and three recent FDA agents approved for treatment.

Expert dermatologists discuss factors guiding treatment selection in plaque psoriasis and the role of emerging novel topical agents.

An expert panel discusses new evidence to guide personalized care in heart failure. They focus on updates in the most recent heart failure guidelines, review guideline-directed medical therapy, and discuss the new clinical trial data in specific patient populations.

Experts in hepatology discuss recent updates in primary biliary cholangitis (PBC) treatment and monitoring. They review recently published real-world data and share their approach to personalizing treatment and what is on the horizon for PBC care.

A panel of experts discuss the role of type 2 inflammation in asthma, challenges with long-term use of corticosteroids, and the emerging role of biologics and various mechanisms of actions in the management of asthma.

Experts discuss therapies and sequencing strategies for treating inflammatory bowel disease, highlight the efficacy and safety of these treatments, and explore prospective advances in the care of patience with inflammatory bowel disease.

Experts discuss gut microbiota, current and emerging microbiome-based therapies for C difficile, and the practical ways to incorporate these treatments into your clinical practice.

A panel of medical experts discuss the current treatment landscape surrounding atopic dermatitis.

Experts in dermatology focus on how new and advanced treatments are impacting the quality of life for individuals with atopic dermatitis (AD). They explore how to optimize the patient experience by utilizing these therapies in a strategic matter.

Experts in dermatology discuss the pathophysiology of vitiligo, current standards of care, and new and emerging therapies. They also explore evidence-based approaches and patient-centered care to manage vitiligo and improve patient outcomes.

In this upcoming program, experts discuss the importance of correct diagnosis and early treatment of rare dermatologic disorders and best practices for critical care physicians in managing these conditions.

Experts discuss several topics pertaining to dry eye disease, including challenges and unmet needs, current and emerging treatment options, and tailoring treatment strategies based on individual patient factors.

Expert retina specialists discuss long-term experience with anti-VEGF therapies for age-related macular degeneration and diabetic macular edema, and share evidence-based strategies to improve treatment outcomes.

Updates in the management of immune-mediated kidney diseases; challenges in diagnosis of immunoglobulin A nephropathy (IgAN) and C3 glomerulopathy (C3G), current management and emerging treatment options.

In this program, our expert panel discusses several topics pertaining to type 1 diabetes, including screening and diagnosis, current and emerging treatments, and the role of clinicians in early testing and patient education.

Expert dermatologists discuss 3 patient case scenarios and their approach to finding the best treatment for each patient type. They discuss data, pros and cons of use of various classes of treatments, approaches to monitoring the disease, and changing treatment based on patient and disease characteristics.

Experts in psychiatry focus on treatment options for major depressive disorder (MDD). The discussion centers on data with newer mechanisms of action, new and emerging treatment options, and management of MDD in specific patient populations and how new treatments are aiming to fulfill unmet needs in MDD.

Advanced practice providers in dermatology discuss the treatment landscape for the management of plaque psoriasis. They review available and emerging treatment options, highlighting recent approvals and long-term safety and efficacy data.

Expert dermatologists discuss diagnosis and treatment of prurigo nodularis (PN). They review data for the only FDA-approved treatment for prurigo nodularis and the implications of the results in management of the disease.

Rheumatology specialists discuss challenges in the management of rheumatoid arthritis (RA), and how the trial-and-error approach to treatment selection and continued use of ineffective treatments impacts quality of life in RA. The panel discusses tools available to guide treatment selection and how personalization of care can improve treatment outcomes.

Experts gastroenterologists share insights on optimizing the management of Crohn’s disease, focusing on the current treatment landscape and the role of biologic therapy.

Retina specialists discuss clinical burden of geography atrophy, its current management, data with emerging treatment options, and the promise newer therapies might offer for treatment of geographic atrophy.

In this upcoming HCPLive program, experts review available and emerging treatment options for the management of plaque psoriasis, highlighting recent approvals and long-term safety and efficacy data.

Key opinion leaders discuss management of attention deficit hyperactivity disorder (ADHD) in pediatric and adult population and how the emerging data are likely to influence treatment of ADHD in adult patients going forward.

Expert health professionals provide key insights on recently approved SARS-CoV-2 booster shots highlighting current recommendations and optimizing patient communication and education on vaccination options.

Experts in cardiology discuss the management of hypercholesterolemia and atherosclerotic cardiovascular diseases (ASCVD), the importance of achieving LDL-C lowering goals, and treatment of hypercholesterolemia in patients who are statin-intolerant.